Systemic lupus erythematosus (SLE) is a chronic condition that can affect multiple tissues and organs. Learn about symptoms, causes, treatments, and more.

Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." What causes SLE? Experts ...

Super League Announces 1-for-40 Reverse Split. SANTA MONICA, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Super League Enterprise, Inc. (Nasdaq: SLE) (the “Company”), a leader in engaging ...

Super League Enterprise (SLE) delivered earnings and revenue surprises of -28.57% and 31.48%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for ...

Adicet Bio receives FDA Fast Track designation for ADI-001 for the treatment of refractory systemic lupus erythematosus (SLE) with extrarenal involvement. News release. Adicet Bio.

This yielded 25,838 with SLE and T2D, of whom 910 initiated a GLP-1 RA and 1004 started a DPP4i, and 12,387 with lupus nephritis and T2D, including 267 on a GLP-1 RA and 324 on a DPP4i.

Super League Enterprise (SLE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $3.47 per share a year ago.